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Abstract
Background. Transmission of HIV through breastfeeding is well documented. The World Health Organisation advise HIV-
infected women in developed countries to use alternatives to breastfeeding together with highly active antiretroviral therapy
and optimal management of delivery to prevent transmission of HIV to their infant.
Case report. We present the case of an HIV-infected woman electing to exclusively breastfeed for six months and applying
milk pasteurisation techniques without transmission to her infant. Two paired samples of her breast milk were tested for HIV
RNA prior to and after pasteurisation. The ﬁrst pair of specimens reported no change in HIV RNA copy number, the second
pair of specimens reported an increase in copy number.
Discussion. This technique, the evidence for HIV inactivation and the effects pasteurisation has on nutritional and
immunological components of breast milk are discussed.
Conclusion. In conclusion, we believe there is currently insufﬁcient data to recommend this technique either as a safe
alternative to formula feeding in resource-rich countries or as a method for providing intact immunological components of
breast milk to the infant.
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Introduction
HIV has been detected in breast milk and transmis-
sion can occur at any point during lactation, the
cumulative probability of infection increasing with
the duration of breastfeeding. In a meta-analysis of
late postnatal transmission (deﬁned as an infant with
negative HIV-1 result at 4 weeks of age followed by a
positive test result) the overall risk was 8.9 transmis-
sions per 100 child-years of breastfeeding (95%
conﬁdence interval 7.8–10.2 transmissions/100 child
years of breastfeeding) [1–3]. Factors associated with
increased rates of HIV transmission include mixed
feeding (breastfeeding supplemented by formula and
other bottle feeding) [4] high maternal viral load,
prolonged breastfeeding and breastfeeding in the
presence of mastitis or breast abscesses [5,6].
In resource-rich countries breastfeeding is not
recommended, but the World Health Organization
suggests that breastfeeding should still be the usual
advice to pregnant women in countries where
infectious diseases and malnutrition are the main
causes of infant deaths and infant mortality is high [7].
HIV is inactivated by heating and reports in the
literature have suggested that pasteurisation in a
domestic setting may be a method for enabling HIV-
infected women to breastfeed [8]. We report the case of
a woman attempting to apply the technique of breast
milk pasteurisation in a developed country in order to
enable her infant access to the beneﬁts of breastfeeding
(immunological, nutritional and psychological) and the
results from testing her milk for HIV.
Case report
This case is of a 34-year-old woman who acquired her
HIV in Africa in 1994 following a sexual contact. In
January 1997 she commenced antiretroviral therapy
comprising of zidovudine, lamivudine and indinavir.
Her viral load dropped from 396000 copies/mL to
undetectable. In July 1997 she ceased indinavir
when she decided to become pregnant. After ceasing
indinavir her viral load again became detectable at
1400 copies/mL. She soon became pregnant and
continued on zidovudine and lamivudine for the
remainder of her pregnancy. Her viral load remained
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ranging between 400 and 1000 copies/mL. In May
1998 she underwent an elective caesarean section,
she did not breastfeed and her baby who received
oral zidovudine syrup for six weeks, remained
uninfected.
In February 1999 the patient ceased all antire-
trovirals for a ﬁve-month period. Her viral load at
this time peaked at greater than 750000copies/mL
and her CD4 count dropped to 396 (28%). She
recommenced therapy in July 1999 with stavudine,
lamivudine and efavirenz. Her viral load became
undetectable and her CD4 count rose (ranging
between 777 and 1000). The patient decided again
to cease all medication in October 2001.
In July 2002, she presented eight weeks pregnant.
At this time she was off antiretroviral therapy, her
CD4 count was 550 (19%) and her viral load 14000
copies/mL. The patient commenced antiretrovirals
at 19 weeks gestation on zidovudine, lamivudine and
nevirapine. She had an uneventful pregnancy and
underwent an elective caesarean section in February
2003. At this time her viral load was undetectable.
Her baby received oral zidovudine syrup and despite
medical advice the patient proceeded to breastfeed
using pasteurised breast milk after the ﬁrst week. For
the ﬁrst week the patient used donor milk from a
friend and did not pasteurise this. After the ﬁrst week
she exclusively breastfed and pasteurised her milk at
home. The method of pasteurisation used was the
Holder technique [9]. This involved heating water in
an urn to 658C then placing a sterilized jar containing
the breast milk into the urn so the water level was
over the milk level. A thermometer placed in the jar
monitored the temperature and aimed to keep the
milk at 648C for 30min. The milk was then removed
and provided to the infant in a bottle. This continued
for six months and she did not report any mastitis or
nipple problems during this time. She remained on
the same antiretrovirals with her plasma viral load
less than 400copies/mL.
Two paired specimens of breast milk were
analyzed pre- and post-pasteurisation for HIV viral
load. The ﬁrst paired specimens of breast milk were
sent to the State Reference Laboratory for HIV and
underwent HIV RNA quantiﬁcation by NASBA.
HIV RNA was detected at less than 250 copies/mL
both pre- and post-pasteurisation. The second pair of
specimens were tested at the same State Reference
Laboratory for HIV using the Roche ULTRA PCR
(polymerase chain reaction) four months later and
the breast milk sample prior to pasteurisation had
60copies/mL and the breast milk sample post-
pasteurisation had 80copies/mL. The methods and
performance characteristics of these assays for
quantiﬁcation of HIV RNA in plasma have pre-
viously been described [10].
The patient’s son tested at six months remained
uninfected with HIV.
Discussion
HIV is easily inactivated by heat. Holder pasteurisa-
tion used by human milk banks (568C for 30min)
has resulted in the inactivation of all detectable virus
by repeat culture in human milk inoculated with HIV
[11]. A method called Pretoria pasteurisation has
been devised in an attempt to heat the milk in a
domestic environment in a way that prevents the
milk becoming too hot and destroying immunologi-
cal components although still reaching sufﬁcient
temperature for the inactivation of HIV [8]. This
method involves heating a 1 L aluminium pot con-
taining 450 mL of water to boiling then removing
from the heat source and placing a jar containing
50–150 mL of milk into the water. By following this
procedure the milk temperature remains between 56
and 62.58C for between 10 and 15 min. It is not clear
whether 15 min is sufﬁcient to inactivate all cell-free
and cell-associated HIV in breast milk.
In an attempt to answer this question the same
group of researchers performed a prospective ob-
servational study to test the effectiveness of Pretoria
pasteurisation to inactivate HIV in human breast
milk. Milk samples from HIV-seropositive women
were split into two portions: a control and a study
portion. These were sampled for HIV RNA and HIV
DNA PCR and immediately inoculated into lym-
phocyte culture for 35 days. Twenty-six samples
from HIV-seropositive women were tested. Eighty
percent of these had viral RNA detected prior to
pasteurisation (mean milk viral load 422000copies/
mL) but none of the pasteurised specimens showed
increasing titres of viral RNA. In two of the speci-
mens viral RNA was detectable in the pasteurised
specimens but at low levels [12]. Of the HIV-positive
control specimens, 18% had evidence of viral repli-
cation. In our case report, there is a relatively low
level of virus detected in the milk sample prior to
pasteurization, which may impact on the magnitude
of effect demonstrable by pasteurisation, although it
is important to note that the copy number did
increase in the second specimen.
One of the main reasons why HIV-positive women
in developed countries desire to breastfeed is to
provide for their infant a source of milk that contains
not only all their nutritional requirements but also has
immunological components not found in formula
feed.Animportantquestiontherefore,iswhatdoesthe
processofheat pasteurisation doto these components?
Immunomodulating factors and antimicrobial
agents found in breast milk include proteins such
as lactoferrin (chelates iron), lysozyme (degrades
peptidoglycans), ﬁbronectin (acts as an opsonin),
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act as opsonins), lipids (known to disrupt enveloped
viruses) and cytokines such as interleukin-1b and
interleukin-6 (activates T cells and enhances IgA
production) [13]. Pasteurisation at 628C for 30min
leads to a reduction in IgA, lactoferrin, lysozyme, cell
number and function [14].
Holder pasteurisation has also been shown to
signiﬁcantly lower the concentrations of vitamin C
(36%), folacin (31%) and B6 (15%) [15]. Pasteur-
isation also reduces enzyme activity including lipase,
amylase and lactoperoxidase [16] along with serum-
stimulated lipolytic and serum-independent lipolytic
activity [17].
As treatment and prognosis for HIV-seropositive
women in resource-rich countries improves many are
contemplating having children. Many interventions
have been demonstrated to reduce perinatal trans-
mission such as antiretroviral therapy [18] elective
caesarean section [19] and avoidance of breastfeed-
ing, although much of this beneﬁt has been studied
prior to the availability of highly active antiretroviral
therapy (HAART). Studies have demonstrated that
women with a higher breast milk viral load and those
who shed virus consistently rather than intermittently
are more likely to transmit HIV to their infants [6]. It
is important to note that cell-associated HIV-1
provirus in the breast milk has been reported despite
low/undetectable plasma viremia [20]. There is a
paucity of data on additional risk of transmission via
breastfeeding in women with undetectable viral load
and who undertake additional measures such as milk
pasteurisation.
The only antiretrovirals known to be excreted in
human breast milk are zidovudine, lamivudine and
nevirapine. Many of the remaining antiretrovirals
have been found in breast milk in animal studies but
lack data on excretion in human breast milk [21].
As clinicians looking after these women, it is
essential that we are aware of the literature describing
these techniques. As our case report highlights, HIV-
seropositive women may decide to access this
information and apply these techniques to facilitate
breastfeeding. The testing we employed demon-
strated the presence of HIV post-pasteurisation. We
believe it is essential to conduct further studies to
assess the safety of this technique and to investigate
the effect HAART may have on viral load pre- and
post-pasteurisation. In such a study it would also be
important to document more formally the effect this
technique has on the many immunological factors
present in breast milk as it is for this reason that
many women are keen to breastfeed. Women
infected with HIV in developed countries who desire
to breastfeed and employ breast milk pasteurisation
need to be informed regarding the effect this may
have on inactivating HIV along with the potential
adverse effects this process may have on the
immunological components contained within breast
milk. At this time we believe there is insufﬁcient data
to recommend this technique as a safe alternative to
formula feeding in resource-rich countries.
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